DECISION OF THE EEA JOINT COMMITTEE No 172/2025

of 11 July 2025

amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2025/2108]

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area ("the EEA Agreement"), and in particular Article 98 thereof,

Whereas:

(1) Regulation (EU) 2024/1860 of the European Parliament and of the Council of 13 June 2024 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, the obligation to inform in case of interruption or discontinuation of supply, and transitional provisions for certain *in vitro* diagnostic medical devices ([1]) is to be incorporated into the EEA Agreement.

(2) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

The following indent is added in points 11 (Regulation (EU) 2017/745 of the European Parliament and of the Council) and 12 (Regulation (EU) 2017/746 of the European Parliament and of the Council) of Chapter XXX of Annex II to the EEA Agreement:

'— **32024 R 1860**: Regulation (EU) 2024/1860 of the European Parliament and of the Council of 13 June 2024 (OJ L, 2024/1860, 9.7.2024).'

Article 2

The text of Regulation (EU) 2024/1860 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the *Official Journal of the European Union*, shall be authentic.

Article 3

This Decision shall enter into force on 12 July 2025, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*).

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the *Official Journal of the European Union*.

Done at Brussels, 11 July 2025.

For the EEA Joint Committee
The President
Kristján Andri STEFÁNSSON

([1]) OJ L, 2024/1860, 9.7.2024, ELI: http://data.europa.eu/eli/reg/2024/1860/oj.
(*) Constitutional requirements indicated.